NewLake Capital Partners Issues Second Quarter 2026 Common Stock Dividend of $0.43 per Share

NewLake Capital Partners (OTCQX: NLCP) said its board approved a Q2 2026 cash dividend of $0.43 per common share, annualized at $1.72. The dividend is payable July 15, 2026, to shareholders of record June 30. The company reported 100% of contractual rent collected in Q2 2026 and said the dividend is supported by portfolio earnings.

Original reporting
Published Jun 12, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
NewLake Capital Partners Issues Second Quarter 2026 Common Stock Dividend of $0.43 per Share — source image
Decision brief

The 30-second read

$NLCPBullishLow
01

Why it matters

The company ties the declared dividend to portfolio earnings and reports 100% contractual rent collected for Q2 2026, which may reduce perceived near-term cash-flow risk.

02

Market read

A scheduled dividend with explicit coverage/rent-collection commentary can influence short-horizon positioning around record/ex-dividend timing.

03

What to watch

Because the stock is OTCQX-listed, liquidity and dividend-related flows may dominate price action more than fundamentals; traders should watch for any subsequent rent/tenant credit updates.

Relevance 5/10Novelty 6/10Timing: Payable July 15; record date June 30

Background

NewLake is an internally-managed REIT providing real estate capital to state-licensed cannabis operators via sale-leasebacks and build-to-suit projects.

Company-level read

Ticker impact

$NLCPBullishMedium confidence
Context

NewLake Capital Partners announced its board approved a $0.43 Q2 2026 common dividend, payable July 15 to holders of record June 30.

Expected impact

Likely modest positive bias around ex-dividend/record-date expectations; limited upside unless dividend sustainability or rent collection changes.

Evidence & confidence

This is a concrete, time-bound corporate action (dividend amount and dates) with an explicit support claim (earnings/100% rent collected), but it is not an earnings/guidance revision or balance-sheet change.

Market effects

Reinforces the ‘rent collection supports dividends’ narrative for cannabis real-estate REITs, but no new sector-wide regulatory or demand signal is provided.

None indicated.

None indicated.

Counterpoint

Dividend support is asserted, but the release doesn’t provide new financial metrics (e.g., AFFO/coverage ratio), so sustainability risk may be underappreciated.

Key entities

  • NewLake Capital Partners, Inc.

    OTCQX-listed cannabis real-estate REIT that declared a $0.43 Q2 2026 dividend with specified record and payable dates.

Related articles

$NLCPMed

NewLake Capital Partners Reports Third Quarter 2026 Financial Results

NewLake Capital Partners, Inc. (NLCP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99-1 NewLake Capital Partners Reports Third Quarter 2026 Financial Results Third Quarter 2026 Revenue Totaled $12.0 Million Third Quarter 2026 Net Income Attributable to Common Stockholders Totaled $4.2 Million, Funds from Operations Totaled $10.0 Million, and Adjusted Fu

$NLCPMed

NewLake Capital Partners Reports Second Quarter 2026 Financial Results

NewLake Capital Partners, Inc. (NLCP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99-1 NewLake Capital Partners Reports Second Quarter 2026 Financial Results Second Quarter 2026 Revenue Totaled $12.1 Million Second Quarter 2026 Net Income Attributable to Common Stockholders Totaled $5.9 Million, Funds from Operations Totaled $9.9 Million, and Adjusted

$NVSMed

Novartis is said to be abandoning Ionis heart drug after late-stage trial setback

Novartis NVS is halting development of Ionis IONS's heart drug pelacarsen after it failed a late-stage trial. The therapy did not meet its primary endpoint in the Lp(a)HORIZON trial for cardiovascular disease. Novartis will continue testing pelacarsen for calcific aortic valve stenosis. Amgen AMGN, Arrowhead ARWR, and Royalty Pharma RPRX also saw shares drop in September due to the setback.